Neurobiological Technologies Dividends
| NTII Stock | USD 0.0001 0.00 0.000003% |
The current Dividends Paid is estimated to decrease to about 20.1 M. The Neurobiological Technologies' current Dividend Paid And Capex Coverage Ratio is estimated to increase to -8,974. Neurobiological Technologies' past performance could be the main factor of why investors trade Neurobiological Technologies stock today. Investors should clearly understand every aspect of the Neurobiological Technologies dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Neurobiological Technologies' dividend schedule and payout information. Neurobiological Technologies dividends can also provide a clue to the current valuation of Neurobiological Technologies.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 22.6 M | 20.1 M | |
| Dividend Paid And Capex Coverage Ratio | -9.4 K | -9 K |
Neurobiological | Build AI portfolio with Neurobiological Stock |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Neurobiological Technologies must own a stock before its ex-dividend date to receive its next dividend.
Neurobiological Technologies Dividends Paid Over Time
Today, most investors in Neurobiological Technologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neurobiological Technologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Neurobiological Technologies dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is there potential for Biotechnology market expansion? Will Neurobiological introduce new products? Factors like these will boost the valuation of Neurobiological Technologies. Anticipated expansion of Neurobiological directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Neurobiological Technologies's market price often diverges from its book value, the accounting figure shown on Neurobiological's balance sheet. Smart investors calculate Neurobiological Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Neurobiological Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neurobiological Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurobiological Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.